EVENT January 23, 2018

NobleCon 14 Annual Investor Conference

Date:  Tuesday, January 30, 2018 Time:  2:30 P.M. EST Room:  Studio 1 Location:  W Fort Lauderdale, 401 N Fort Lauderdale Beach Blvd, Fort Lauderdale, FL 33304 Webcast:  http://noble.mediasite.com/mediasite/Play/187d50750006440a800ea4e8bcf113e11d 

Keep Reading

PRESS RELEASE January 23, 2018

Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Englewood Cliffs, New Jersey, USA- January 23, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets’ Fourteenth Annual Investor Conference, to be held January 29-30 at the W Hotel in […]

Keep Reading

January 23, 2018

Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Englewood Cliffs, New Jersey, USA- January 23, 2018 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets’ Fourteenth Annual Investor Conference, to be held January 29-30 at the […]

Keep Reading

PRESS RELEASE January 10, 2018

Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid Englewood Cliffs, NJ- January 10, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that an abstract detailing positive interim […]

Keep Reading

January 10, 2018

Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid Englewood Cliffs, New Jersey, USA – January 10, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that an abstract […]

Keep Reading

EVENT January 4, 2018

Biotech Showcase™ Annual Conference

Date:  Wednesday, January 10, 2018 Time: 9:30 A.M. PST Room: Yosemite – A (Ballroom Level) Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (USA) Webcast: https://event.webcasts.com/starthere.jsp?ei=1176714&tp_key=ab81c8f855  

Keep Reading

January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Englewood Cliffs, New Jersey, USA – January 8, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare investment forums at […]

Keep Reading

PRESS RELEASE January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Englewood Cliffs, NJ- January 4,2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare investment forums at the Hilton San Francisco […]

Keep Reading

December 14, 2017

Immune Pharmaceuticals Announces Change in Certifying Accountant

Englewood Cliffs, NJ, USA – December 14, 2017 – Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP (“BDO”) the Company’s independent registered public accounting firm for the […]

Keep Reading